FDA Raises Profile Of “Bad Ad” Program With Its Own Ads
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency continues to publicize the program for health care professionals and the public to report misleading drug promotion.
You may also be interested in...
"Bad Ad" Program Set To Expand After Opening Spigot Of Complaints In Year One
In its first year of operation, FDA's "Bad Ad" program succeeded in more than tripling the number of complaints the agency receives about deceptive drug advertising, and now the agency is assessing how best to expand upon the success of the initiative.
FDA Deputizes Doctors In Hunt For "Bad Ads"
Outreach program, which asks for tips on worrisome promotional behavior, might be an effective deterrent even without finding many violations.
Janssen’s Sirturo Needs Minor Tweaks To Confirmatory Trial, FDA Panel Says
Gathering more data to assuage concerns about possibly lower efficacy in black patients will be key to converting the accelerated approval to full approval for the tuberculosis drug, FDA’s Anti-Infective Drugs Advisory Committee concludes.